Clinical Trial

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-12.
Status change: Not Yet Recruiting → Recruiting 2025-01-14
Trial Details
NCT Number NCT06600022
Lead Sponsor Sinocelltech Ltd.
Conditions Advanced Malignant Solid Tumours
Enrollment 441 participants
Start Date 2024-10-10
Primary Completion 2027-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-16